Aligos Completes HBV Phase 2 Enrollment; Execution On Track

What happened

Aligos Therapeutics announced completion of enrollment in the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV, covering both HBeAg+ and HBeAg- patients. This milestone reflects operational execution but does not yet provide efficacy data or derisk the program's ultimate potential. The company’s HBV pipeline remains a key watch item, though near-term catalysts still hinge on data readouts and partnering for both HBV and MASH programs. With $122.9M in cash, Aligos has runway into mid-2026, but the pre-revenue status and competitive landscape keep risk/reward balanced. We maintain our HOLD stance pending more substantive catalysts.

Implication

The completion of enrollment in the Phase 2 B-SUPREME study is a positive operational step, demonstrating Aligos' ability to execute on its HBV program. While this reduces near-term execution risk, it does not provide efficacy readouts that would alter the risk/reward profile. Investors should continue to focus on upcoming data readouts and partnering developments for both HBV and MASH programs. The balance sheet remains adequate for at least 12 months, but additional capital or partnerships will be needed for later-stage trials. We maintain our HOLD stance pending more substantive catalysts.

Thesis delta

The news confirms that Aligos' HBV program is progressing on schedule, reducing some operational uncertainty. However, the core thesis remains unchanged—value inflection depends on data and partnerships. We still need to see efficacy signals and a clear regulatory/partnering path to become more constructive.